

The following message was sent to you through the Alaska Public Health Alert Network (AK PHAN). Please share this information with others who may be interested.

Note: [Contact information for the Alaska Section of Epidemiology can be found at the end of this message.](#)

## **Recommendations for the Use of Respiratory Syncytial Virus (RSV) Vaccine in Pregnancy – Update for the Alaska 2023-2024 Season**

**January 26, 2024**

### **Summary**

Given current circulation of respiratory syncytial virus (RSV) and the suboptimal supply of Nirsevimab, the Alaska Section of Epidemiology (SOE) **recommends continuing to offer RSVpreF (Pfizer, Abrysvo) vaccination during 32-36 weeks of pregnancy until further notice.**

### **Background**

- The respiratory virus season is well underway with varying shifts in pathogen dominance since September: [AK DOH Respiratory Virus Snapshot](#). RSV circulation remains steady in Alaska.
- The Advisory Committee on Immunization Practices (ACIP) recommended that vaccination in pregnancy should end January 31, acknowledging that jurisdictions could consider locally-tailored recommendations, especially in areas known to have more unique circulation of RSV such as in Alaska.
- Nirsevimab is a product recommended for use in infants; however, unstable supply has meant not all eligible infants have been immunized. Vaccinating with RSVpreF during late pregnancy is a complementary strategy to ensure that infants can be protected through passive immunity.
- This is the first RSV season where there have been prevention products available and as such recommendations are evolving.

### **Vaccine Recommendation Extension**

- Given current circulation of respiratory syncytial virus (RSV) and the suboptimal supply of Nirsevimab, the Alaska SOE **recommends continuing to offer RSVpreF vaccination during 32-36 weeks of pregnancy until further notice.**
- We plan to seek CDC/expert guidance about further extending recommendations to maximize protection of infants, as well as to simplify implementation for health care providers and improve consistency in messaging for vaccinations during pregnancy.

### **Resources**

- Alaska SOE RSVpreF *Bulletin*: [https://epi.alaska.gov/bulletins/docs/b2023\\_17.pdf](https://epi.alaska.gov/bulletins/docs/b2023_17.pdf)
- Alaska DOH Respiratory Virus Snapshot: <https://health.alaska.gov/dph/Epi/id/Pages/COVID-19/covidandflu.aspx>
- Alaska SOE RSV Webpage: <https://health.alaska.gov/dph/Epi/id/Pages/dod/rsv/default.aspx>
- CDC: [ACIP Evidence to Recommendations for Use of Pfizer RSVpreF in Pregnant People](#)
- CDC: [Healthcare Providers: RSV Vaccination for Pregnant People](#)
- CDC: [Frequently Asked Questions about RSVpreF \(ABrysvo\) Vaccine for Pregnant People](#)